RxDoctor Payments Data

Robert Dowell

Family · Knoxville, TNNPI 1487818712

Payments from drug & device makers

$15,555in general payments, 2019–2025

Across 1,068 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$1K
  • GSK$1K
  • Lilly USA, LLC$979
  • Pfizer$827
  • Otsuka America Pharmaceutical, Inc.$771
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,38199%
  • Education$1741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie227$2,843
Novo Nordisk97$1,283
GSK86$1,207
Lilly USA, LLC73$979
Pfizer79$827
Otsuka America Pharmaceutical, Inc.51$771
AstraZeneca41$762
Amgen52$638
Axsome Therapeutics, Inc.24$459
Amarin Pharma, Inc.23$416
Bayer24$411
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)18$390
Esperion Therapeutics, Inc.21$373
Boehringer Ingelheim31$370
Takeda Pharmaceuticals U.S.A., Inc.22$347
Abbott19$343
Jazz Pharmaceuticals Inc.11$248
Johnson & Johnson10$226
Sumitomo Pharma America, Inc.17$219
Astellas Pharma US Inc7$188
Xeris Pharmaceuticals, Inc.10$186
Lundbeck LLC10$181
Vanda Pharmaceuticals Inc.5$141
Medtronic8$134
Phathom Pharmaceuticals, Inc.7$123
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$119
Dexcom, Inc.5$108
E.r. Squibb & Sons, L.L.C.6$95
Kowa Pharmaceuticals America, Inc.7$94
Sunovion Pharmaceuticals Inc.7$85
Merck5$80
Biohaven Pharmaceuticals, Inc.5$79
Alkermes, Inc.3$58
Arbor Pharmaceuticals, Inc.4$57
Novartis2$52
Antares Pharma, Inc.3$46
Phadia US Inc.2$42
Sanofi-aventis U.S. LLC3$40
Biohaven Pharmaceutical Holding Company Ltd.2$35
Scilex Pharmaceuticals Inc.2$35
Nevro Corp.2$32
Mannkind Corporation2$32
Mylan Specialty L.p.2$32
Teva Pharmaceuticals USA, Inc.2$31
Inogen, Inc.2$30
Corium, LLC1$29
Eisai Inc.2$28
Halozyme Inc2$28
Nabriva Therapeutics, PLC2$27
Tonix Medicines, Inc.1$26
Insulet Corporation1$20
Mycovia Pharmaceuticals, Inc.1$20
Eyevance Pharmaceuticals LLC1$20
Hikma Pharmaceuticals USA1$20
Harmony Biosciences LLC1$18
Almatica Pharma LLC1$17
Intersect ENT, Inc.1$16
Clarus Therapeutics Inc.4$16
Impel Pharmaceuticals Inc.1$14
Amneal Pharmaceuticals LLC1$12

How this compares

$15,555 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$48,085
Medicare patients
153
Services billed
1,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide226$295,213
OzempicSemaglutide143$166,467
JardianceEmpagliflozin90$106,503
EliquisApixaban97$103,166
FarxigaDapagliflozin Propanediol76$77,344
JanuviaSitagliptin Phosphate49$76,859
RinvoqUpadacitinib11$66,214
VraylarCariprazine Hcl41$63,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$54,653
Tresiba Flextouch U-200Insulin Degludec34$47,156
MyrbetriqMirabegron53$43,635
CreonLipase/Protease/Amylase13$40,792
RexultiBrexpiprazole23$39,180
RybelsusSemaglutide15$35,766
Spiriva RespimatTiotropium Bromide31$29,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$979$309,620237 claims
AbbVieRinvoq, Vraylar, Creon, Linzess, Ubrelvy$2,843$216,280105 claims
Novo NordiskOzempic, Rybelsus, Novolog$1,283$208,552172 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$370$145,905136 claims
PfizerEliquis, Premarin$827$111,641109 claims
AstraZenecaFarxiga, Symbicort, Brilinta, Bevespi Aerosphere$762$109,574152 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,207$78,58297 claims
MerckJanuvia$80$76,85949 claims
Astellas Pharma US IncMyrbetriq$188$43,63553 claims
Otsuka America Pharmaceutical, Inc.Rexulti$771$39,18023 claims
Johnson & JohnsonXarelto$226$28,96030 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$347$17,78928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →